Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3797) 3797
science & technology (2443) 2443
life sciences & biomedicine (2245) 2245
leukemia, myeloid, acute - enzymology (1391) 1391
biological and medical sciences (1165) 1165
hematology (1082) 1082
female (1062) 1062
oncology (1059) 1059
male (1055) 1055
medical sciences (1026) 1026
leukemia (909) 909
adult (874) 874
animals (848) 848
middle aged (778) 778
hematologic and hematopoietic diseases (759) 759
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (722) 722
aged (624) 624
leukemia, myeloid - enzymology (573) 573
leukemia - enzymology (549) 549
leukemia, myeloid, acute - pathology (493) 493
mice (473) 473
cell line, tumor (471) 471
leukemia, myeloid, acute - drug therapy (468) 468
adolescent (458) 458
leukemia, myeloid, acute - genetics (456) 456
abridged index medicus (433) 433
child (413) 413
acute disease (410) 410
apoptosis (408) 408
cancer (407) 407
cell biology (404) 404
mutation (398) 398
apoptosis - drug effects (396) 396
antineoplastic agents - pharmacology (343) 343
research (326) 326
tumor cells, cultured (325) 325
hemic and lymphatic diseases (309) 309
acute myeloid leukemia (302) 302
antineoplastic agents (300) 300
cell line (298) 298
leukemia, lymphoid - enzymology (290) 290
biochemistry & molecular biology (289) 289
protein kinase inhibitors - pharmacology (285) 285
proteins (280) 280
signal transduction (273) 273
pharmacology. drug treatments (272) 272
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (271) 271
antineoplastic agents - therapeutic use (269) 269
genetic aspects (263) 263
gene expression (262) 262
precursor cell lymphoblastic leukemia-lymphoma - enzymology (255) 255
child, preschool (251) 251
chemotherapy (246) 246
prognosis (245) 245
leukocytes - enzymology (241) 241
bone marrow - enzymology (236) 236
tumors (235) 235
research article (227) 227
phosphorylation (226) 226
analysis (214) 214
protein kinase inhibitors - therapeutic use (210) 210
kinases (208) 208
leukemia, myeloid - pathology (207) 207
cell differentiation (204) 204
enzymes (197) 197
science & technology - other topics (197) 197
multidisciplinary sciences (195) 195
cell proliferation - drug effects (194) 194
enzyme inhibitors - pharmacology (192) 192
fundamental and applied biological sciences. psychology (188) 188
leukemia - pathology (187) 187
histocytochemistry (185) 185
time factors (182) 182
medicine (181) 181
signal transduction - drug effects (181) 181
aged, 80 and over (179) 179
cell differentiation - drug effects (175) 175
health aspects (174) 174
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (165) 165
pharmacology & pharmacy (162) 162
leukemia, myeloid, acute - blood (161) 161
hl-60 cells (159) 159
drug resistance, neoplasm (158) 158
chronic myeloid leukemia (156) 156
physiological aspects (156) 156
flow cytometry (155) 155
myeloid leukemia (153) 153
stem cells (152) 152
care and treatment (148) 148
cell cycle (147) 147
imatinib mesylate (147) 147
infant (147) 147
dose-response relationship, drug (144) 144
leukemia - drug therapy (144) 144
science (144) 144
medicine, research & experimental (143) 143
research & experimental medicine (143) 143
bone marrow - pathology (141) 141
tyrosine (140) 140
drug resistance (139) 139
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3776) 3776
German (85) 85
Russian (57) 57
French (44) 44
Japanese (44) 44
Chinese (28) 28
Polish (20) 20
Italian (17) 17
Czech (7) 7
Spanish (4) 4
Dutch (3) 3
Bulgarian (2) 2
Croatian (2) 2
Serbian (2) 2
Ukrainian (2) 2
Danish (1) 1
Hungarian (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Isocitrate dehydrogenase mutations in myeloid malignancies
by Medeiros, B.C and Fathi, A.T and DiNardo, C.D and Pollyea, D.A and Chan, S.M and Swords, R
Leukemia, ISSN 0887-6924, 02/2017, Volume 31, Issue 2, pp. 272 - 281
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Prognosis | Isoenzymes | Gene Frequency | Humans | Leukemia, Myeloid, Acute - epidemiology | Isocitrate Dehydrogenase - genetics | Myelodysplastic Syndromes - epidemiology | Biomarkers, Tumor | Myelodysplastic Syndromes - enzymology | Leukemia, Myeloid, Acute - mortality | Leukemia, Myeloid, Acute - enzymology | Animals | DNA Mutational Analysis | Isocitrate Dehydrogenase - metabolism | Myelodysplastic Syndromes - genetics | Mutation | Leukemia, Myeloid, Acute - genetics | Care and treatment | Research | Isocitrate dehydrogenase | Myelodysplastic syndromes | Krebs cycle | Mutation (Biology) | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-6-Methyladenosine RNA Demethylase
by Li, Zejuan and Weng, Hengyou and Su, Rui and Weng, Xiaocheng and Zuo, Zhixiang and Li, Chenying and Huang, Huilin and Nachtergaele, Sigrid and Dong, Lei and Hu, Chao and Qin, Xi and Tang, Lichun and Wang, Yungui and Hong, Gia-Ming and Huang, Hao and Wang, Xiao and Chen, Ping and Gurbuxani, Sandeep and Arnovitz, Stephen and Li, Yuanyuan and Li, Shenglai and Strong, Jennifer and Neilly, Mary Beth and Larson, Richard A and Jiang, Xi and Zhang, Pumin and Jin, Jie and He, Chuan and Chen, Jianjun
Cancer cell, ISSN 1535-6108, 01/2017, Volume 31, Issue 1, pp. 127 - 141
Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Cell Proliferation | Leukemia, Myeloid, Acute - pathology | Alpha-Ketoglutarate-Dependent Dioxygenase FTO - physiology | Humans | Transcriptome | Leukemia, Myeloid, Acute - etiology | Retinoic Acid Receptor alpha - physiology | Leukemia, Myeloid, Acute - enzymology | Adenosine - analogs & derivatives | Adenosine - metabolism | Leukemia, Myeloid, Acute - drug therapy | Suppressor of Cytokine Signaling Proteins - physiology | Methylation | Apoptosis | Tretinoin - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Sorafenib treatment of FLT3-ITD + acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
by Man, Cheuk Him and Fung, Tsz Kan and Ho, Christa and Han, Heron H. C and Chow, Howard C. H and Ma, Alvin C. H and Choi, William W. L and Lok, Si and Cheung, Alice M. S and Eaves, Connie and Kwong, Yok Lam and Leung, Anskar Y. H
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 22, pp. 5133 - 5143
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Neoplasm Transplantation | Humans | Middle Aged | Aldehyde Dehydrogenase - biosynthesis | Matrix Metalloproteinase 15 - genetics | Male | Transplantation, Heterologous | Bone Marrow - enzymology | Gene Expression Profiling | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Benzenesulfonates - adverse effects | Retinal Dehydrogenase | Janus Kinase 3 - biosynthesis | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Pyridines - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aldehyde Dehydrogenase 1 Family | Protein Structure, Tertiary | Pyridines - administration & dosage | Leukemia, Myeloid, Acute - pathology | Aldehyde Dehydrogenase - genetics | Gene Expression Regulation, Leukemic | Mice, SCID | fms-Like Tyrosine Kinase 3 - metabolism | Matrix Metalloproteinase 15 - biosynthesis | Drug Resistance, Neoplasm - genetics | Animals | Bone Marrow - pathology | Sorafenib | Janus Kinase 3 - genetics | Mice, Inbred NOD | Mice | Mutation | Drug Resistance, Neoplasm - drug effects | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
by Okoye-Okafor, Ujunwa C and Bartholdy, Boris and Cartier, Jessy and Gao, Enoch N and Pietrak, Beth and Rendina, Alan R and Rominger, Cynthia and Quinn, Chad and Smallwood, Angela and Wiggall, Kenneth J and Reif, Alexander J and Schmidt, Stanley J and Qi, Hongwei and Zhao, Huizhen and Joberty, Gerard and Faelth-Savitski, Maria and Bantscheff, Marcus and Drewes, Gerard and Duraiswami, Chaya and Brady, Pat and Groy, Arthur and Narayanagari, Swathi-Rao and Antony-Debre, Iléana and Mitchell, Kelly and Wang, Heng Rui and Kao, Yun-Ruei and Christopeit, Maximilian and Carvajal, Luis and Barreyro, Laura and Paietta, Elisabeth and Makishima, Hideki and Will, Britta and Concha, Nestor and Adams, Nicholas D and Schwartz, Benjamin and McCabe, Michael T and Maciejewski, Jaroslav and Verma, Amit and Steidl, Ulrich and Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Nature chemical biology, ISSN 1552-4450, 11/2015, Volume 11, Issue 11, pp. 878 - 886
Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Neoplastic Stem Cells - drug effects | Allosteric Regulation | Humans | Crystallography, X-Ray | Male | Isocitrate Dehydrogenase - antagonists & inhibitors | Dose-Response Relationship, Drug | Leukemia, Myeloid, Acute - enzymology | Pyrazoles - chemistry | Enzyme Inhibitors - pharmacokinetics | Granulocytes - drug effects | Cytosine - metabolism | Dihydropyridines - pharmacokinetics | Enzyme Inhibitors - chemistry | Leukemia, Myeloid, Acute - drug therapy | Neoplastic Stem Cells - pathology | Granulocytes - pathology | Pyrazoles - pharmacokinetics | Pyrazoles - pharmacology | Dihydropyridines - chemistry | Leukemia, Myeloid, Acute - pathology | Enzyme Inhibitors - pharmacology | Models, Molecular | Isocitrate Dehydrogenase - genetics | Cytosine - chemistry | Granulocytes - enzymology | Xenograft Model Antitumor Assays | Animals | Cell Differentiation - drug effects | Isocitrate Dehydrogenase - chemistry | Allosteric Site | Cell Line, Tumor | CpG Islands | Dihydropyridines - pharmacology | Protein Binding | Isocitrate Dehydrogenase - metabolism | Mice | Kinetics | Mutation | Primary Cell Culture | DNA Methylation - drug effects | Neoplastic Stem Cells - enzymology | Leukemia, Myeloid, Acute - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text IDH mutations in glioma and acute myeloid leukemia
by Dang, Lenny and Jin, Shengfang and Su, Shinsan M
Trends in molecular medicine, ISSN 1471-4914, 2010, Volume 16, Issue 9, pp. 387 - 397
Pathology | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Brain Neoplasms - enzymology | Glioma - enzymology | Humans | Brain Neoplasms - genetics | Isocitrate Dehydrogenase - genetics | Glioma - genetics | Leukemia, Myeloid, Acute - enzymology | Animals | Isocitrate Dehydrogenase - chemistry | Brain Neoplasms - therapy | Glioma - therapy | Isocitrate Dehydrogenase - metabolism | Mutation | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Enzymes | Gliomas | Genetic aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
by Zimmerman, Eric I and Zimmerman, Eric I and Turner, David C and Turner, David C and Buaboonnam, Jassada and Buaboonnam, Jassada and Hu, Shuiying and Hu, Shuiying and Orwick, Shelley and Orwick, Shelley and Roberts, Michael S and Roberts, Michael S and Janke, Laura J and Janke, Laura J and Ramachandran, Abhijit and Ramachandran, Abhijit and Stewart, Clinton F and Stewart, Clinton F and Inaba, Hiroto and Inaba, Hiroto and Baker, Sharyn D and Baker, Sharyn D
Blood, ISSN 0006-4971, 2013, Volume 122, Issue 22, pp. 3607 - 3615
Life Sciences & Biomedicine | Hematology | Science & Technology | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Humans | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Tandem Repeat Sequences | Antineoplastic Agents - administration & dosage | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Benzimidazoles - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Female | Piperidines - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Benzimidazoles - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Piperidines - administration & dosage | Benzimidazoles - pharmacokinetics | Mice, SCID | Niacinamide - administration & dosage | Drug Synergism | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Phenylurea Compounds - administration & dosage | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Cell Line, Tumor | Mice, Inbred NOD | Mice | Mutation | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus | Myeloid Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
by Strati, Paolo and Kantarjian, Hagop and Ravandi, Farhad and Nazha, Aziz and Borthakur, Gautam and Daver, Naval and Kadia, Tapan and Estrov, Zeev and Garcia‐Manero, Guillermo and Konopleva, Marina and Rajkhowa, Trivikram and Durand, Menda and Andreeff, Michael and Levis, Mark and Cortes, Jorge
American journal of hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. 276 - 281
Life Sciences & Biomedicine | Hematology | Science & Technology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Azacitidine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Myelodysplastic Syndromes - enzymology | Dose-Response Relationship, Drug | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Drug Administration Schedule | Staurosporine - adverse effects | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Staurosporine - therapeutic use | Myelodysplastic Syndromes - mortality | Aged | Mutation | Azacitidine - therapeutic use | Staurosporine - administration & dosage | Index Medicus | AML | AZA | midostaurin | MDS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
by Metzelder, S.K and Schroeder, T and Lübbert, M and Ditschkowski, M and Götze, K and Scholl, S and Meyer, R.G and Dreger, P and Basara, N and Fey, M.F and Salih, H.R and Finck, A and Pabst, T and Giagounidis, A and Kobbe, G and Wollmer, E and Finke, J and Neubauer, A and Burchert, A
European journal of cancer (1990), ISSN 0959-8049, 11/2017, Volume 86, pp. 233 - 239
Acute myeloid leukemia | FLT3-ITD | Sorafenib | Hematopoietic stem cell transplantation | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Recurrence | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Tandem Repeat Sequences | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Retrospective Studies | Leukemia, Myeloid, Acute - therapy | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Remission Induction | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Adolescent | Aged | Biomarkers, Tumor - genetics | Germany | Leukemia, Myeloid, Acute - genetics | Stem Cell Transplantation - adverse effects | Antimitotic agents | Tyrosine | Relapse | Care and treatment | Analysis | Patient outcomes | Stem cells | Transplantation | Antineoplastic agents | Hematopoietic stem cells | Diseases | Transplants & implants | Leukemia | Stem cell transplantation | Remission | Flt3 protein | Patients | Protein-tyrosine kinase | Survival | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights